Mark Rothera
2019 - Orchard Therapeutics plc
In 2019, Mark Rothera earned a total compensation of $4.3M as Former CEO at Orchard Therapeutics plc.
Compensation breakdown
| Non-Equity Incentive Plan | $369,208 |
|---|---|
| Option Awards | $3,330,458 |
| Salary | $525,350 |
| Other | $87,973 |
| Total | $4,312,989 |
Rothera received $3.3M in option awards, accounting for 77% of the total pay in 2019.
Rothera also received $369.2K in non-equity incentive plan, $525.4K in salary and $88K in other compensation.
Rankings
In 2019, Mark Rothera's compensation ranked 2,702nd out of 13,971 executives tracked by ExecPay. In other words, Rothera earned more than 80.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,702 out of 13,971 | 81st |
Division Manufacturing | 975 out of 5,695 | 83rd |
Major group Chemicals And Allied Products | 320 out of 2,194 | 85th |
Industry group Drugs | 261 out of 1,880 | 86th |
Industry Biological Products, Except Diagnostic Substances | 63 out of 389 | 84th |
Source: SEC filing on April 28, 2021.
Rothera's colleagues
We found two more compensation records of executives who worked with Mark Rothera at Orchard Therapeutics plc in 2019.